IDENTIFICATION AND MANAGEMENT OF PERSONS WITH CHRONIC VIRAL HEPATITIS IN EUROPE

Viral Hepatitis Prevention Board
Budapest, Hungary
March 18-19, 2010
The Viral Hepatitis Prevention Board

18 years of support to the control and prevention of viral hepatitis in Europe.
Content

• Viral Hepatitis Prevention Board (VHPB)
• VHPB activities
• Hepatitis B control in Europe
Viral Hepatitis Prevention Board

• The objective of VHPB is to contribute to the control and prevention of viral hepatitis
  - by drawing the attention to this important public health problem
  - by issuing prevention guidelines
  - and by encouraging actions to improve control and prevention.

• VHPB focus audiences are, in first instance, opinion leaders, policymakers, and health care professionals.
• VHPB was established in 1992. First actions related to hepatitis B as an occupational risk.
• World Health Assembly (1992): Integration of hepatitis B vaccine into national vaccination programmes.
• In 1993, VHPB started a second major initiative and focused on hepatitis B as a community health risk.
• The geographical focus was initially Western Europe, its actions are extended to include all 53 countries in the WHO/EURO
Support and Grants

- **VHPB secretariat**
  - based at the Center for the Evaluation of Vaccination (CEV) of the University of Antwerpen
  - infrastructure and administrative services of the University
- **supported by**
  - unrestricted grants from the vaccine industry GlaxoSmithKline Biologicals, Sanofi Pasteur MSD, Sanofi Pasteur and Merck
  - several universities and other institutions in Europe
  - GAVI fund and the CVP at PATH in the past for its activities in CEE and NIS.
- **strict operational and scientific independence is essential**
  - VHPB advisers and invited experts get only travel and subsistence reimbursed
  - according to the University Rules
  - no honorary or other forms of remuneration
Viral Hepatitis Prevention Board

- **Members**
  - WHO/EURO, WHO/HQ, ECDC, CDC, MOH, University experts

- network of experts
<table>
<thead>
<tr>
<th><strong>WHO</strong></th>
<th><strong>ECDC</strong></th>
<th><strong>CDC</strong></th>
<th><strong>ELPA (European liver patients association)</strong></th>
<th><strong>Public Health Institute</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nedret Emiroglu</td>
<td>WHO Regional office for Europe</td>
<td>Marita Van de Laar</td>
<td>ECDC, Sweden</td>
<td>Hans Blystad</td>
</tr>
<tr>
<td>Daniel Lavanchy</td>
<td>WHO Headquarter</td>
<td></td>
<td></td>
<td>David Goldberg</td>
</tr>
<tr>
<td>Steven Wiersma</td>
<td>WHO Headquarter</td>
<td></td>
<td></td>
<td>Johannes Hallauer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>John Ward</td>
<td>CDC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nicole Piorkowsky</td>
<td>ELPA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Honorary members</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pietro Crovan</td>
<td>Italy</td>
<td>Eric Mast</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Alain Goudeau</td>
<td>France</td>
<td>Elisabeth McCloy</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Nicole Guérin</td>
<td>France</td>
<td>André Meheus</td>
<td>Belgium</td>
<td></td>
</tr>
<tr>
<td>Peter Grob</td>
<td>Swiss</td>
<td>Lars Rombo</td>
<td>Sweden</td>
<td></td>
</tr>
<tr>
<td>Mark Kane</td>
<td>USA</td>
<td>Colette Roure</td>
<td>France</td>
<td></td>
</tr>
<tr>
<td>Harold Margolis</td>
<td>Korea</td>
<td>Lars Rombo</td>
<td>Sweden</td>
<td></td>
</tr>
</tbody>
</table>
Viral Hepatitis Prevention Board

- Meetings
  - 2 - 3 meetings/year (technical – country)
- Viral Hepatitis Newsletter
  - 2 issues/year
  - mailing to ± 4000 readers
- Web site
- Scientific publications
- Participation at Scientific Meetings
Editorial

This issue of Viral Hepatitis reviews the topics covered at the Viral Hepatitis Prevention Board (VHPB) autumn meeting held on November 17-18, 2005 in Edinburgh, United Kingdom (UK). The aim of the meeting was to review the current UK practice relating to the control of viral hepatitis. Health policy, healthcare delivery, decision-making, research, and funding in England, Wales, Scotland, and Northern Ireland were examined, in particular with regards to their implementation at national level. An update on the epidemiological situation of hepatitis A, hepatitis B, and hepatitis C in the UK was provided. Specific aspects of viral hepatitis were discussed, including virological and clinical aspects, control measures, public health perspectives, and economic evaluations. Preventive national and regional strategies for the control of viral hepatitis in the UK were then presented and assessed, including testing, vaccination, and treatment options. The meeting was concluded with lessons learnt from the UK experience and future challenges to be met.

Control of viral hepatitis in the UK - achievements and challenges

With regards to the decision-making process ensuring prevention of viral hepatitis, the need was recognised for a continuous evaluation of the current risk-group vaccination policy, to be compared with results obtained with alternative strategies, such as universal vaccination programmes, in other comparable countries of the European Union. The need to carefully monitor such alternative strategies implemented at the regional level in the UK was recognised. The need to target specific groups, such as immigrant populations, in preventive programmes and treatment was also identified.

In terms of chronic disease management, discussions focused on the need for national strategy and action plan in the case of hepatitis B while the establishment of Managed Clinical Networks (MCNs) should be ensured in the case of hepatitis C.

The control of viral hepatitis in the United Kingdom was also seen to be lacking a reliable surveillance system, based on standard laboratory reporting and case notifications. The need for enhanced epidemiological data was mentioned in or-
Viral Hepatitis Prevention Board

- Meetings
  - 2 - 3 meetings/year
- *Viral Hepatitis* Newsletter
  - 2 issues/year
  - mailing to ± 4000 readers
- Scientific publications
- Participation at Scientific Meetings
- Web site
Web site www.vhpb.org

- Web site
  - Overview of the VHPB
  - Show all previous recommendations, guidelines and consensus statements
  - All *Viral Hepatitis* issues as of 1996 can be downloaded
  - Presentations of VHPB meetings are on-line since 2001 (>374 presentations of in total >471 documents)
WHO issued a review of the position paper on Hepatitis B vaccines.

The October 2 issue of the WHO periodical "Weekly Epidemiological Record" covered the latest WHO position paper on hepatitis B vaccines. To access it, go to:

All WHO position papers on vaccines are available in alphabetical order at
http://www.who.int/immunization/documents/positionpapers.

---

**Viral Hepatitis, Volume 17, Number 2, prepared from material presented at meeting 'Prevention and control of viral hepatitis in the Netherlands: Lessons learnt and the way forward' is online.** 1,461Kb (.pdf)

This issue of Viral Hepatitis fully focuses on the Netherlands and reviews the organization of the healthcare system, the epidemiological situation, surveillance system, research activities, and current prevention and control measures of viral hepatitis. It also includes the meeting discussions that were particularly interesting as the Dutch Ministry of Health was re-evaluating the possible introduction of universal hepatitis B vaccination into the National Immunization programme at the time of this VHPB meeting.
Meetings and Recommendations

The VHPB has already covered a broad range of control and prevention strategies for all forms of hepatitis

- Surveillance
- Universal Immunisation programs
- Injection safety and safe blood supply
- HBV mutants and variants
- Prevention and control of viral hepatitis in migrants and refugees
- Behavioural issues in hepatitis B vaccination
- How to reach risk groups
- Combined vaccines
- Economic evaluations
- Hepatitis B vaccination safety issues
- Hepatitis B vaccine and long term efficacy
- Hepatitis infections in health care workers
- Perinatal transmission
- Adolescent programmes
- Patient and advocacy groups
- Hepatitis A and E
Abstract

In March 2009 the Viral Hepatitis Prevention Board (VHPB) organized a meeting in Antwerp, in order to review the status of epidemiology and prevention of both hepatitis A and E. International hepatitis experts from the public health and academic sector provided the state of the art on HAV and emphasized the growing public health importance of the disease, in particular in intermediate endemicity regions, and the need for control at global level. The information shared on HEV showed clearly that it is emerging, but still a lot of efforts are needed to clarify among others the transmission routes, the clinical presentations and the burden of disease. First data on hepatitis E vaccines were discussed, showing a promising safety and efficacy profile. The meeting was concluded with lessons learnt, challenges, needs and proposed step forwards for both diseases.
Hepatitis A and B vaccination and public health

F. Blaine Hollinger, B. Bell, D. Levy-Bruhl, D. Shouval, S. Wiersma and P. Van Damme

1Baylor College of Medicine, Houston, TX, USA; 2Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA; 3Institut de Veille Sanitaire, Saint-Maurice, France; 4Hadassah University Hospital, Jerusalem, Israel; 5World Health Organization, Geneva, Switzerland; and 6Center for the Evaluation of Vaccination, University of Antwerp, Antwerp, Belgium

Received July 2007; accepted for publication August 2007

SUMMARY. The introduction and implementation of hepatitis B vaccination programmes in areas of high endemicity has been very stressful. However, this initial accomplishment has led to the reassessment of priorities in some countries which could undermine these early successes. Work still remains to be done to support and implement interventions that will bring us closer to the WHO goal and to the control of hepatitis B in the community at large. Hepatitis A vaccine strategy for immunizing toddlers is shifting to those countries with intermediate endemicity where increasing morbidity in adults is being observed. Accumulating evidence indicates that such programmes can result in impressive reductions in the incidence of hepatitis A by herd immunity. Monitoring of these populations to determine durability of protection will be important to avoid shifting the infection to the older age population, when symptoms are more likely to occur. National policies need to consider hepatitis A vaccination in the context of other public health priorities.

Keywords: epidemiology, hepatitis A vaccine, hepatitis B vaccine, vaccine prevention.

INTRODUCTION

Hepatitis B immunization for infants and preschool children, even in low endemicity countries.
Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology

G. Hendrickx,1 K. Van Herck,1,2 A. Vorsters,1 S. Wiersma,3 C. Shapiro,4 J. K. Andrus,5 A. M. Ropero,5 D. Shouval,6 W. Ward3 and P. Van Damme1 1Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium; 2Postdoctoral Fellow, Research Foundation – Flanders (FWO), Brussels, Belgium; 3Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA; 4Department of Immunizations, Vaccines & Biologicals, World Health Organization, HQ, Geneva, Switzerland; 5Pan American Health Organization, Washington, DC, USA; and 6Liver Unit, Hadassah-Hebrew University Hospital, Jerusalem, Israel

SUMMARY. For the first time a global meeting on hepatitis A virus (HAV) infection as vaccine preventable disease was organized at the end of 2007. More than 200 experts from 46 countries gathered to investigate the changing global HAV epidemiology reflecting the increasing numbers of persons at risk for severe clinical disease and mortality from HAV infection. The benefits of childhood and adult hepatitis A (HepA) vaccination strategies and the data needed by individual countries and international health organizations to assess current HepA prevention strategies were discussed. New approaches in preventing HAV infection including universal HepA vaccination were considered. This introductory paper summarizes the major findings of the meeting and describes the changing epidemiology of HAV infections and the impact of HepA vaccination strategies in various countries. Implementation of HepA vaccination strategies should take into account the level of endemicity, the level of the socio-economic development and sanitation, and the risk of outbreaks. A stepwise strategy for introduction of HepA universal immunisation of children was recommended. This strategy should be based on accurate surveillance of cases and qualitative documentation of outbreaks and their control, secure political support on the basis of high-quality results, and comprehensive cost-effectiveness studies. The recognition of the need for increased global attention towards HepA prevention is an important outcome of this meeting.

Keywords: Global hepatitis A meeting, hepatitis A, hepatitis A vaccination, infectious disease control, public health, surveillance.
Benefits of Early Hepatitis B Immunization Programs for Newborns and Infants

Koen Van Herck, MD, PhD,*† and Pierre Van Damme, MD, PhD*

Abstract: Despite the availability of safe and effective hepatitis B virus (HBV) vaccines for >20 years, strategies targeting risk groups failed to sufficiently control hepatitis B disease at the population level; this is mainly because of difficulties in risk identification and in program implementation. Hence, the global burden of disease of HBV still is substantial.

The World Health Organization recommends universal vaccination against hepatitis B to ultimately eliminate HBV; this recommendation had been progressively implemented to reach 168 countries with a universal program by the end of 2006. However, hepatitis B immunization is currently becoming endangered of losing its place on the agendas of governments, agencies, and international organizations, mainly because of the increasing success of these immunization programs and the interest in newer vaccine-preventable diseases and the related programs.

This publication aims to show that vaccination programs targeting newborns and infants are preferable to achieve this goal. The benefits of universal HBV vaccination for newborns and infants are: higher impact on chronic carrier rate and transmission; established potential of high vaccine coverage in this age group; opportunities to combine HBV vaccination with existing universal vaccination programs for newborns and infants; and impact on perinatal transmission, if vaccination is started shortly after birth. Moreover, the safety, immunogenicity, and long-term efficacy of newborn and infant HBV vaccination

Key Words: universal immunization, vaccination programs, hepatitis B vaccination, public health

(Pediatr Infect Dis J 2008;27: 861–869)

The success of vaccination programs so far and the interest in other vaccine-preventable diseases have led to hepatitis B virus (HBV) vaccination becoming endangered of losing its place on the agenda of governments, agencies, and international organizations, a topic recently discussed at the Viral Hepatitis Prevention Board meeting in Istanbul, Turkey.1 Some agencies are downgrading HBV vaccination and have become reluctant to divert resources to HBV immunization programs,1 while clearly, the burden of HBV disease, compared with vaccine-preventable childhood diseases, is still substantial even in countries with low HBV endemicity.2–8 HBV infection continues to be a serious global health problem, with 2 billion people infected worldwide, and 350 million suffering from chronic HBV infection.9

On the basis of HBV epidemiologic data, a mathematical model was developed to estimate the global hepatitis B disease burden and vaccination impact.10 During the lifetime of the year 2000 worldwide birth cohort, the model estimates that without vaccination there would be 64,766,000 HBV infections; 9,733,000 chronic infections; and 1,405,000 HBV-related
Country meetings

- Italy 2002
- Germany and the Nordic Countries 2003
- France 2004
- UK 2005
- Spain 2006
- Greece 2007
- The Netherlands 2008
- Turkey 2009
- Portugal 2010
IDENTIFICATION AND MANAGEMENT OF PERSONS WITH CHRONIC VIRAL HEPATITIS IN EUROPE

Viral Hepatitis Prevention Board
Budapest, Hungary
March 18-19, 2010
• Why this meeting:

Recently different organizations took the initiative to promote screening and identification of persons with chronic hepatitis. As the implementation of screening programmes can have a tremendous impact on a country’s health care system and on its citizens, the VHPB advisors were convinced that is was important to discuss this trend.
Objectives of the meeting (1)

- To take stock of the current screening of chronic diseases and lessons learnt.
- To apply the screening criteria (the Wilson and Jungner criteria) on the identification of persons with chronic hepatitis.
- To report on HTA (health technology assessment) of such identification programmes.
- To learn how screening and the management of the identified persons can reduce the morbidity and mortality of chronic viral hepatitis.
Objectives of the meeting (2)

• To discuss if the potential benefits of identifying chronic viral hepatitis and preventing the development of the health problem outweigh the cost and potential harm associated with the screening process.

• List the conditions required for the successful implementation

• Discuss strength and weaknesses of screening as well as other public health and social aspects or consequences.

• Evaluate the impact of a diagnosis on individual well being